4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl] -2H-phthalazin-1-one: A novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1

Journal of Medicinal Chemistry

Volumn 51, Issue 20, 2008, Pages 6581-6591

  Menear, Keith A ^a   Adcock, Claire ^a   Boulter, Robert ^a   Cockcroft, Xiao Ling ^a   Copsey, Louise ^a   Cranston, Aaron ^a   Dillon, Krystyna J ^a   Drzewiecki, Jan ^a   Garman, Sheila ^a   Gomez, Sylvie ^a   Javaid, Hashim ^a   Kerrigan, Frank ^b   Knights, Charlotte ^a   Lau, Alan ^a   Loh Jr , Vincent M ^a   Matthews, Ian T W ^a   Moore, Stephen ^a   O'Connor, Mark J ^a   Smith, Graeme C M ^a   Martin, Niall M B ^a  

^a KuDOS Pharmaceuticals Ltd   (United Kingdom)

^b Thermo Fisher Scientific   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 (4 CYCLOPROPANECARBONYLPIPERAZINE 1 CARBONYL) 4 FLUOROBENZYL] 2H PHTHALAZIN 1 ONE; AZD 2281; BRCA1 PROTEIN; KU 0059436; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER MODEL; COLORECTAL CANCER; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DISTRIBUTION VOLUME; DNA DAMAGE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG POTENCY; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG TARGETING; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; RAT; SINGLE DRUG DOSE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE; CELL SURVIVAL; DOGS; ENZYME INHIBITORS; HUMANS; MICE; MOLECULAR STRUCTURE; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 54549103449     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8001263     Document Type: Article

References (45)

1. D'Amours, D.; Desnoyers, S.; D'Silva, I.; Poirier, G. G. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem. J. 1999, 342, 249-268.
2. d'Adda di Fagagna, F.; Hande, M. P.; Tong, W. M.; Lansdorp, P. M.; Wang, Z. Q.; Jackson, S. P. Functions of poly(ADP-ribose) polymerase in controlling telomere length and chromosomal stability. Nat. Genet. 1999, 23, 76-80.
3. Virag, L.; Szabo, C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol. Rev. 2002, 54, 375-429.
4. Ame, J. C.; Spenlehauer, C.; de Murcia, G. The PARP superfamily. BioEssays 2004, 26, 882-893.
5. Diefenbach, J.; Burkle, A. Introduction to poly(ADP-ribose) metabolism. Cell. Mol. Life Sci. 2005, 62, 721-730.
6. Huber, A.; Bai, P.; de Murcia, J. M.; de Murcia, G. PARP-1, PARP-2, and ATM in the DNA damage response: functional synergy in mouse development. DNA Repair 2004, 3, 1103-1108.
7. Kickhoefer, V. A.; Siva, A. C.; Kedersha, N. L.; Inman, E. M.; Ruland, C.; Streuli, M.; Rome, L. H. The 193-kD vault protein, VPARP, is a novel poly(ADP-ribose) polymerase. J. Cell Biol. 1999, 146, 917-928.
8. Smith, S.; Giriat, I.; Schmitt, A.; de Lange, T. Tankyrase, a poly(ADP-ribose) polymerase at human telomeres. Science 1998, 282, 1484-1487.
9. Althaus, F. R.; Richter, C. ADP-ribosylation of proteins. Enzymology and biological significance. Mol. Biol., Biochem. Biophys. 1987, 37, 1-237.
10. Le Rhun, Y.; Kirkland, J. B.; Shah, G. M. Cellular responses to DNA damage in the absence of poly(ADP-ribose) polymerase. Biochem. Biophys. Res. Commun. 1998, 245, 1-10.
11. Wang, Z. Q.; Auer, B.; Stingl, L.; Berghammer, H.; Haidacher, D.; Schweiger, M.; Wagner, E. F. Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease. Genes Dev. 1995, 9, 509-520.
12. Ménissier de Murcia, J.; Niedergang, C.; Trucco, C.; Ricoul, M.; Dutrillaux, B.; Mark, M.; Oliver, F. J.; Masson, M.; Dierich, A.; LeMeur, M.; Walztinger, C.; Chambon, P.; de Murcia, G. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 7303-7307.
13. Ben-Hur, E.; Utsumi, H.; Elkind, M. M. Inhibitors of poly(ADP-ribose) synthesis enhance radiation response by differentially affecting repair of potentially lethal versus sublethal damage. Br. J. Cancer, Suppl. 1984, 6, 39-42.
14. Schlicker, A.; Peschke, P.; Burkle, A.; Hahn, E. W.; Kim, J. H. 4-Amino-1,8-naphthalimide: a novel inhibitor of poly(ADP-ribose) polymerase and radiation sensitizer. Int. J. Radiat. Biol. 1999, 75, 91-100.
15. Durkacz, B. W.; Omidiji, O.; Gray, D. A.; Shall, S. (ADP-ribose)n participates in DNA excision repair. Nature 1980, 283, 593-596.
16. Berger, N. A. Poly(ADP-ribose) in the cellular response to DNA damage. Radiat. Res. 1985, 101, 4-14.
17. Jagtap, P.; Szabo, C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat. Rev. Drug Discovery 2005, 4, 421-440.
18. De la Lastra, C. A.; Villegas, I.; Sanchez-Fidalgo, S. Poly(ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications. Curr. Pharm. Des. 2007, 13, 933-962.
19. Delaney, C. A.; Wang, L.-Z.; Kyle, S.; White, A. W.; Calvert, H.; Curtin, N. J.; Durkacz, B. W.; Hostomsky, Z.; Newell, D. R. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin. Cancer Res. 2000, 6, 2860-2867.
20. Miknyoczki, S. J.; Jones-Bolin, S.; Pritchard, S.; Hunter, K.; Zhao, H.; Wan, W.; Ator, M.; Bihovsky, R.; Hudkins, R.; Chatterjee, S.; Klein-Szanto, A.; Dionne, C.; Ruggeri, B. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol. Cancer Ther. 2003, 2, 371-382.
21. Tentori, L.; Graziani, G. Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol. Res. 2005, 52, 25-33.
22. Narod, S. A.; Foulkes, W. D. BRCA1 and BRCA2: 1994 and beyond. Nat. Rev. Cancer. 2004, 4, 665-676.
23. Bryant, H. E.; Schultz, N.; Thomas, H. D.; Parker, K. M.; Flower, D.; Lopez, E.; Kyle, S.; Meuth, M.; Curtin, N. J.; Helleday, T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434, 913-917.
24. Farmer, H.; McCabe, N.; Lord, C. J.; Tutt, A. N. J.; Johnson, D. A.; Richardson, T. B.; Santarosa, M.; Dillon, K. J.; Hickson, I.; Knights, C.; Martin, N. M. B.; Jackson, S. P.; Smith, G. C. M.; Ashworth, A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434, 917-921.
25. Jasin, M. Homologous repair of DNA damage and tumorigenesis: the BRCA connection. Oncogene 2002, 21, 8981-8993.
26. Tutt, A.; Ashworth, A. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol. Med. 2002, 8, 571-576.
27. Radice, P. Mutations of BRCA genes in hereditary breast and ovarian cancer. J. Exp. Clin. Cancer Res. 2002, 21, 9-12.
28. Hoeijmakers, J. H. Genome maintenance mechanisms for preventing cancer. Nature 2001, 411, 366-374.
29. Bernstein, C.; Bernstein, H.; Payne, C. M.; Garewal, H. DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat. Res. 2002, 511, 145-178.
30. Kennedy, R. D.; D'Andrea, A. D. DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. J. Clin. Oncol. 2006, 24, 3799-3808.
31. Ratnam, K.; Low, J. A. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin. Cancer Res. 2007, 13, 1383-1388.
32. Thomas, H. D.; Calabrese, C. R.; Batey, M. A.; Canan, S.; Hostomsky, Z.; Kyle, S.; Maegley, K. A.; Newell, D. R.; Skalitzky, D.; Wang, L. Z.; Webber, S. E.; Curtin, N. J. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol. Cancer Ther. 2007, 6, 945-956.
33. Mason, K. A.; Valdecanas, D.; Hunter, N. R.; Milas, L. INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin. Invest. New Drugs 2008, 26, 1-5.
34. Donawho, C. K.; Luo, Y.; Luo, Y.; Penning, T. D.; Bauch, J. L.; Bouska, J. J.; Bontcheva-Diaz, V. D.; Cox, B. F.; DeWeese, T. L.; Dillehay, L. E.; Ferguson, D. C.; Ghoreishi-Haack, N. S.; Grimm, D. R.; Guan, R.; Han, E. K.; Holley-Shanks, R. R.; Hristov, B.; Idler, K. B.; Jarvis, K.; Johnson, E. F.; Kleinberg, L. R.; Klinghofer, V.; Lasko, L. M.; Liu, X.; Marsh, K. C.; McGonigal, T. P.; Meulbroek, J. A.; Olson, A. M.; Palma, J. P.; Rodriguez, L. E.; Shi, Y.; Stavropoulos, J. A.; Tsurutani, A. C.; Zhu, G. D.; Rosenberg, S. H.; Giranda, V. L.; Frost, D. J. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin. Cancer Res. 2007, 13, 2728-2737.
35. Yap, T. A. First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients (p), including BRCA1/2 mutation carriers. Presented at the 43rd Annual Meeting of the ASCO, Chicago, IL, June 1-5, 2007; Abstr. No. 3529.
36. Banasik, M.; Komura, H.; Shimoyama, M.; Ueda, K. Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase. J. Biol. Chem. 1992, 267, 1569-1575.
37. Banasik, M.; Ueda, K. Inhibitors and activators of ADP-ribosylation reactions. Mol. Cell. Biochem. 1994, 138, 185-197.
38. Kamanaka, Y.; Kondo, K.; Ikeda, Y.; Kamoshima, W.; Kitajima, T.; Suzuki, Y.; Nakamura, Y.; Umemura, K. Neuroprotective effects of ONO-1924H, an inhibitor of poly ADP-ribose polymerase (PARP), on cytotoxicity of PC12 cells and ischemic cerebral damage. Life Sci. 2004, 76, 151-162.
39. Loh, V. M., Jr.; Cockcroft, X. L.; Dillon, K. J.; Dixon, L.; Drzewiecki, J.; Eversley, P. J.; Gomez, S.; Hoare, J.; Kerrigan, F.; Matthews, I. T.; Menear, K. A.; Martin, N. M.; Newton, R. F.; Paul, J.; Smith, G. C.; Vile, J.; Whittle, A. J. Phthalazinones. Part 1: the design and synthesis of a novel series of potent inhibitors of poly(ADP-ribose)polymerase. Bioorg. Med. Chem. Lett. 2005, 15, 2235-2238.
40. Cockcroft, X. L.; Dillon, K. J.; Dixon, L.; Drzewiecki, J.; Kerrigan, F.; Loh, V. M., Jr.; Martin, N. M.; Menear, K. A.; Smith, G. C. Phthalazinones 2: optimisation and synthesis of novel potent inhibitors of poly(ADP-ribose) polymerase. Bioorg. Med. Chem. Lett. 2006, 16, 1040-1044.
41. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeny, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23, 3-25.
42. Purnell, M. R.; Whish, W. J. Novel inhibitors of poly(ADP-ribose) synthetase. Biochem. J. 1980, 185, 775-777.
43. Dillon, K. J.; Smith, G. C.; Martin, N. M. A FlashPlate assay for the identification of PARP-1 inhibitors. J. Biomol. Screening 2003, 8, 347-352.
44. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 1990, 82, 1107-1112.
45. Hickson, I.; Zhao, Y.; Richardson, C. J.; Green, S. J.; Martin, N. M. B.; Orr, A. I.; Reaper, P. M.; Jackson, S. P.; Curtin, N. J.; Smith, G. C. M. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res. 2004, 64, 9152-9159.